甲强龙与普米克令舒在老年慢性阻塞性肺疾病急性加重期疗效观察  

Observation About the Efficacy of Methylprednisolone and Pulmicort in Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD)

作　　者：马艳[1] 王宾友[1] 易延静[1] 

机构地区：[1]成都市第二人民医院老年科,四川成都610017

出　　处：《四川医学》2016年第2期157-159,共3页Sichuan Medical Journal

摘　　要：目的比较甲强龙与普米克令舒在老年慢性阻塞性肺疾病急性加重期患者的治疗效果及不良反应。方法2010至2011年我科收治的60例65~80岁慢性阻塞性肺疾病急性加重期患者,据入院先后顺序随机分为治疗组1和治疗组2,两组均予以抗感染、祛痰、支气管扩张剂、吸氧等常规治疗措施。治疗组1予以甲强龙40mg静推1次/d;治疗组2予以雾化普米克令舒2mg,2次/d治疗。治疗1周后观察两组的临床症状评分、呼吸困难Borg评分、肺功能、血糖、大便隐血等指标。结果治疗组1较治疗组2咳嗽、喘息症状缓解更明显,更有效改善患者的低氧血症及高碳酸血症,差异有统计学意义（P〈0.05）,不良反应两组差异无统计学意义（P〉0.05）。结论甲强龙短程用于老年COPD急性加重期患者临床疗效确切安全,可有效减轻患者症状及控制病情,并能有效改善患者肺功能。Objective To compare the efficacy and adverse reactions of methylprednisolone and pulmicort in acute exacerbation of COPD.Methods 60 cases of 65 ~ 80 years old patients with acute exacerbation of COPD admitted to Chengdu Second People＇s Hospital geriatrics department in 2010 ~ 2011 years were collected and divided into 2 treatment group randomly according to the order of admission.Two groups were treated with anti infection,eliminating phlegm,bronchodilators,oxygen and other conventional treatment measures. Treatment group 1 received intravenous injection of 40 mg methylprednisolone once a day and treatment group 2 received aerosol inhalation of 2mg pulmicort twice a day.After a week of treatment,the parameters of clinical symptom scores,dyspnea Brog score,pulmonary function,blood sugar,stool occult blood,etc,of two group were observed. Results In treatment group 1,the relief of symptoms like cough and wheeze were more obvious,and the improvement of patients＇ hyoxemia and hypercapnia were better（ P〈0. 05）.There was no obvious difference in side-effect between observational and control group（ P〉0. 05）.Conclusion Short period treatment of methylprednisolone was effective and safe to patients with acute exacerbation of COPD,which could reduce the patients＇ symptoms,control the disease and improve the patient＇s lung function effectively.

关 键 词：甲强龙 普米克令舒 慢性阻塞性肺疾病急性加重期 糖皮质激素 

分 类 号：R563.9[医药卫生—呼吸系统]